You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.
The company said it anticipates using about $25 million to $30 million of the net proceeds for the continued development of its KidneyIntelX platform.
The offering consists of 2 million common shares offered by the company and 1.5 million common shares offered by selling shareholders at a price of $14 per share.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
The cancer molecular diagnostics firm said it will use the proceeds from the offering to support its R&D activities and for general corporate purposes.
CareDx, which focuses on transplant medicine, said it intends to use the proceeds from the offering for working capital and general corporate purposes.
ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.
The Swedish company said it will use the funds in part to accelerate the commercialization of its PanCan-d test for early-stage pancreatic cancer detection.
he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.